Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks
New house I am just trying to get the baby NEW SHOES!
Mani
Dream,
I thought there were a lot of options after scanning yesterday.
Have you "scanned today" yet? WOW!
January is the only month for small caps! lol
Mani
Is Rigs taking the rest of the year off? lol
Good job dayla
Mani
Same here
Just a day early! lol
mani
West keep bankrolling us! lol
Mani
Diluting again call the T/A! Paying salaries?
Volume is drying up what is WTVN going to do now?
He always does this when someone says something he does not agree with! Very mature!lol
Mani
The seem to have lost investor trust with the dilution.
volume is drying up. Keep dumping Mark let's see if anyone buys at .0001
Mani
Dream Call Again ABDE on a tear!
.06 X.095 to .30?
Mani
A newbie! From "Russia with Love" lol LONG!!
UITK @.055 o/s 54 million! Bid ask will settle down at opening.
Sounds like the "Sabre" reservation system of Russia and Eastern Europe.
Ultitek's 15c2-11 Has Been Cleared!
By Market Wire
Last Update: 2/14/2006 8:31:01 AM Data provided by
ENGLEWOOD CLIFFS, NJ, Feb 14, 2006 (MARKET WIRE via COMTEX) -- Ultitek, Ltd. (UITK) (the "Company") announced today that pursuant to NASD Rule 6740 and Rule 15c2-11 of the Securities Exchange Act of 1934, the Company has been cleared for unsolicited quotation on the Pink Sheets LLC for the Company's Common Stock.
Ultitek Ltd.'s wholly owned subsidiary, TAIS, has been a provider of Computerized Airline Reservations Systems software (CRS) since 1989. Today Ultitek Ltd. is the leader among reservations systems in the Russian Aviation market. In 2003, 9 million passengers of 60 airlines were serviced by it, which consisted of more than 50% of the transport of passengers performed on domestic scheduled flights of carriers in Russia and the countries of the C.I.S.
Ultitek, Ltd., through its wholly owned Russian subsidiary, Transport Automation and Information Systems, that has developed and sells and maintains an airline operating, reservation and distribution software system in Eastern Europe. This system is one of the largest multi-hosting airline reservation companies in the world based upon the number of airlines currently utilizing the system (62 airlines worldwide and 5,000 travel agents).
ENGLEWOOD CLIFFS, NJ, Jan 26, 2006 (MARKET WIRE via COMTEX) --Ultitek Ltd. (UITK) is pleased to announce that the Company's un-audited preliminary revenues for 2005 were approximately $1.5 million. This is an increase of one hundred and seventy nine percent (179%) as compared to 2004, when Ultitek realized $836,500 in Gross Revenue.
In 2005 Ultitek's wholly owned subsidiary TAIS continued distributing their Global Airline Scheduling System. They expanded distribution through the development of an agreement with OAG, a global content management company specializing in travel and transport. The company attributes its success to the increase in versatility of their products and efficiency of its stream lined operations.
"We are excited about the progress Ultitek Ltd. has achieved in 2005 and look forward to consistent future gains,'' stated Roman Price, Chairman and CEO of Ultitek, Ltd.
Mani:)
Beautiful wife-snowed in-Hmm!
Stay warm boys! lol
Mani
Penny,
You are welcome.
You have been a great help to me.
Just a heads up.
Mani
MRKL .0249 X 025
MACD ADX +
Moving higher on little volume
Attracting large buys now!!
Mani
MRKL in solid reversal maode
.024 X 0242
Mani
Penny,
I know you are in this did not want to post on WTVN board yet
WTVN O/S has increased 100 milllion plus since last friday.
Mani
Look at NDOL for verification of PR's.
They are happening and AURC is next.
I like "non fluffy" PR's myself, just give me the bottom line.
P.R.s are expensive and the company is spending heir
money wisely by issuing true news.
Mani
This is a paid by the company geologist also.
We have an independent appraisal by a top five world audit firm!!
Mani
EVSC .03 X .031 NEWS!
Ready for second run!
HOUSTON, Feb 09, 2006 (BUSINESS WIRE) -- Endovasc Inc. (EVSC), today announced that the Company has met with their project team at Synergos, the clinical research organization (CRO) that will oversee its upcoming Liprostin clinical trial to finalize the protocol for FDA submission. Additionally, Synergos reviewed a list of clinical sites for the trial and will begin contacting the sites to determine their willingness to join the study and assess potential enrollment.
"Based on the successful completion of a phase II trial, further studies of Liprostin are warranted. We are extremely pleased to be moving forward with the clinical development program for Liprostin and anticipate continued success in the clinical trial process. We will communicate additional developments to our shareholders in the very near future," said Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer.
Endovasc's Liprostin is a liposome-encapsulated from of prostaglandin E-1 (PGE-1). PGE-1 is known to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. In a recently completed Phase II study in patients with peripheral vascular disease, Liprostin treatment significantly improved pain free walking distance. Early phase clinical studies suggest that an encapsulated formulation (Liprostin) can improve the therapeutic index of PGE-1, potentially positively impacting many areas of treatment such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants and arthritis.
About Synergos:
Synergos, Inc. a Contract Research Organization, provides comprehensive clinical research and development services, from study design through regulatory submission. Founded in 1991, Synergos, Inc. has gained substantial experience in pharmaceutical, medical device and biotechnology product development, with significant expertise in numerous therapeutic and diagnostic areas. To date, they have managed studies, analyzed data and produced reports for each type of regulatory submission required by the FDA, including multiple NDAs and PMAs.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing a stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit
www.endovasc.com.
Safe Harbor:
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.
SOURCE: Endovasc Inc.
Mani
Bally,
The big blocks are probably VWKM. eom
Mani
O/T I am your long lost son you never new about! lol
Mani:)
WTVN is on the SHO list.
This helps to keep the price down also.
May be off any day now!
Great West if I had more cash I would too!
Does that make 10 zillion shares? lol
Mani
She is a sweetheart. Isn't she! lol
Mani:)
VCSY looks ready
.0095 X.0099
Mani:)
O/T Thanks. I do have another question.
I am assuming more depth on L2 means more activity.
Comments?
ballyhoo,
O/T
What do you mean by not short due to depth?
Please educate me.
TIA
Mani
Here come the 5's
Thanks :)
Mani
Jcald,
Chart analysis!
My mistake I should have clarified
Mani
All big buys coming in now!!
Mani
Penny-how about a T/A update when possible.
The float should be drying up (volume @ these level).
End of week should be interesting.
Mani:)
MDSM news!!
SCOTTSDALE, Ariz., Feb 06, 2006 (BUSINESS WIRE) -- Medistem Laboratories, Inc. (MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced that it has executed a technology licensing and royalty agreement with the Institute for Cellular Medicine (ICM), an international laboratory and clinic affiliate. The licensure allows ICM to perform clinical programs to further develop Medistem's stem cell therapies and treat patients on a fee-for-service basis at ICM's facility in San Jose, Costa Rica.
The licensing agreement stipulates that ICM will pay royalties to Medistem for the use of Medistem's technologies. In addition to royalties, all intellectual property developed by ICM through their research and clinical treatment programs will be the property of Medistem.
ICM has acquired the lease for their new laboratory and clinical facility. Revenue-generating operations are expected to begin before the end of the second quarter, subsequent to receipt of all necessary government approvals and completion of operational preparations. Medical personnel at ICM's facility will deliver Medistem-developed therapies on a fee-for-service basis, in addition to conducting clinical studies to further develop Medistem technologies and IP portfolio. The clinic will initially focus on stroke patients, with the hope that the therapies will aid in restoring motor skills and other neurological damage caused by stroke.
"The preparation and anticipated opening of the ICM clinical facility next quarter in San Jose, Costa Rica is a major milestone in Medistem's strategic business plan to develop the promise of stem cell therapies for medical care," said Neil Riordan, Ph.D., Chairman and CEO of Medistem. "Research at the world's leading scientific institutions continues to demonstrate the potential of stem cell-derived therapies to provide benefits for people suffering from a wide range of serious diseases, including cancer and chronic neurological and other medical conditions. We are excited to have entered this next phase in our business plan with our colleagues at the Institute for Cellular Medicine."
The execution of the newly completed licensing agreement with ICM and the establishment of the laboratory and clinical facility were key elements of Medistem's recently announced strategic initiatives for the coming 12-month period. Other current Medistem strategic initiatives and goals include the following:
-- Implement revenue-generating business model immediately following opening of ICM clinic via fee-based stem cell treatments using Medistem technology and therapies;
-- Continue laboratory research to develop treatments for stroke and other conditions;
-- Expansion of intellectual property portfolio: Last week, Medistem announced the acquisition of worldwide patent pending rights to a potential treatment for cancer that uses stem cells to reprogram malignant cells to behave like normal cells;
-- Expedite IP expansion through continued clinical developments, particularly of new methods for expansion of stem cell types;
-- Build additional IP through acquisitions of targeted proprietary technologies;
-- Expand business and revenue growth opportunities through replication of fee-for-service revenue model in new global clinics/markets;
-- Identify and pursue establishment of new global locations for clinics, with plans to open clinics approximately every 9-12 months.
About Medistem Laboratories, Inc.
Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications, ultimately be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.
MDSM originally posted @.55
Now .62 X .65
Adult stem cell co.
MACD positive last 4 days
Mani:)
I apologize coming on a little strong at first.
I originally bought WTVN in Dec. I saw you first post about the dillution and sold. I was concerned about a R/S in the future.
Does look like that has stopped. Hopefully paying bill with cash flow now. Yes, this does look to being held down. Hopefully, this will "spring" a nice surprise!
Mani:)
EYII A double in a week!
I have been gone for a while
I think I will have to go again! lol
Mani:)
Patience my son. (lol)
A few more days of this volume and up we go!
Mani
Creede,
Called Friday am.
O/S is the same. :)
Mani:)
Penny are you still buying .0006? lol
Mani